Significant Contract Modifications ($10M+) — August 09, 2026

SIGA TECHNOLOGIES won a $626.5 million firm-fixed-price contract for late-stage development and procurement of a smallpox antiviral drug, with $447.2 million already outlayed and performance through 2029. This provides multi-year revenue visibility (~$56.9M/year) and signals strong government commitment to biodefense preparedness.

QTC Medical Services, a Leidos subsidiary, executed a $209.2 million firm-fixed-price delivery order for VA medical disability exams in the Southeast region, with $196.6 million already outlayed and a one-year performance period ending September 2021. This is a completed contract with no follow-on visibility, limiting its investment catalyst.

OUR RESCUE received a $158.1 million non-competed, time-and-materials contract from HHS for legal services (bridge 2.0), with a 6-month base period and potential total of $244 million. The sole-source nature, high pricing risk, and nonprofit status raise concerns about execution capacity and competitive transparency.

Lockheed Martin received a $999,926 cost-plus-fixed-fee contract from NASA Glenn Research Center for space R&D services (DAMASCUS - CD), with a six-month performance period. The contract is negligible relative to Lockheed Martin's revenue base and offers no material investment signal.

OUR RESCUE's $158.1M non-competed, time-and-materials HHS contract has a short 6-month base period and high pricing risk, with the nonprofit's capacity to execute a contract of this size uncertain.

SIGA TECHNOLOGIES' $626.5M contract is dependent on HHS BARDA's continued biodefense funding, which could be impacted by CRs or budget cuts, though the $447.2M already outlayed reduces near-term risk.

QTC MEDICAL SERVICES' $209.2M VA contract was awarded under full and open competition, and the one-year performance period ended in 2021, meaning Leidos faces re-compete risk for future VA medical disability exam contracts.

SIGA TECHNOLOGIES' $626.5M HHS BARDA contract for smallpox antiviral development could lead to follow-on contracts or option exercises, given the long-term performance period through 2029 and strong government commitment.

OUR RESCUE's $158.1M HHS legal services bridge contract could expand to $244M if all options are exercised, presenting a near-term revenue opportunity for the nonprofit, though execution risk is high.

The $626.5M SIGA TECHNOLOGIES contract from HHS BARDA underscores sustained government investment in biodefense, particularly antiviral development, with multi-year revenue visibility and strong outlay rates.

The $209.2M QTC MEDICAL SERVICES (Leidos) contract for VA medical disability exams in the Southeast region is a completed award, indicating stable demand but with full-and-open competition, suggesting no durable competitive moat.

{"entity" => "SIGA TECHNOLOGIES", "reason" => "Secured a $626.5M long-term HHS BARDA contract with $447.2M already outlayed, providing multi-year revenue visibility.", "trigger" => "Contract modifications or option exercises; quarterly earnings reports for cost performance on fixed-price contract"}

{"entity" => "OUR RESCUE", "reason" => "Received a $158.1M non-competed HHS legal services contract with high execution risk and short base period.", "trigger" => "HHS option exercise decisions before February 2027; potential protests or competitive re-solicitations"}

{"entity" => "Leidos Holdings, Inc.", "reason" => "Subsidiary QTC MEDICAL SERVICES completed a $209.2M VA contract; re-compete risk for future VA medical disability exam contracts.", "trigger" => "VA solicitation for follow-on medical disability exam contracts; Leidos earnings calls for VA contract updates"}